New triple inhaler aims to tame tough asthma

NCT ID NCT07666490

Recruiting now Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests whether a triple-combination inhaler (containing an anti-inflammatory, a long-acting bronchodilator, and another bronchodilator) works better than a standard double-combination inhaler for people whose asthma is not well controlled. About 644 adults with asthma will use one of the two inhalers twice daily for 12 months. The main goal is to see if the triple inhaler improves asthma control scores and reduces flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Beclometasone, formoterol fumarate, and glycopyrronium bromide (Trimbow) triple inhaler
What this could lead to: If successful, this could show that a triple inhaler controls asthma better than a double inhaler for people whose asthma is not well managed.
What could go wrong: This is a phase 4 trial comparing existing drugs, so no major breakthrough is expected. The study is not yet recruiting, and results may show only a small benefit or no difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Medical Center Hermes Ruse LTD 12 Chavdar Voyvoda St.
RECRUITING

Rousse, 7002, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.